Skip to content
Peptide research

HGH Fragment 176-191

Also known as HGH Frag · Frag 176-191
Category
Weight Management & Metabolic
Administration routes
Injectable
Regulatory status
Not FDA-approved

What it is

A synthetic 16-amino-acid piece of growth hormone marketed for targeted fat loss without raising blood sugar or IGF-1. Nearly all supporting human data comes from a related peptide (AOD-9604), not this exact fragment, so real human evidence is thin and rests mostly on animal and mechanism studies. No published human safety trials exist for the unmodified peptide, and unregulated products sold online vary widely in quality. Not FDA-approved, and prohibited by WADA.

Read Full record

Studied uses & evidence

Studied uses(9)

  • Stimulates lipolysis (fat breakdown) in adipose tissue

    Medium

    The cited rodent, human-tissue, and clinical findings concern related fragments, including AOD-9401 and AOD-9604, rather than a human trial of unmodified hGH 176–191.

  • Inhibits lipogenesis (new fat formation)

    Low

    Shown in animal and ex vivo human tissue studies, but from one research group only.

  • Does not elevate IGF-1 levels

    Speculative

    Shown for the related compound AOD9604 in human trials, not directly tested for this fragment.

Evidence limits

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

Do not use if

  • Active cancer

    Moderate

    Fragment of GH with primarily lipolytic activity. Lower cancer risk than full GH but caution still warranted.

  • Diabetes/hypoglycemia risk

    Moderate

    Can affect glucose metabolism. Monitor blood sugar when combined with antidiabetic agents.

General cautions

  • Pregnancy

    Absolute

    No reproductive safety data for this GH fragment.

Risk summary(12)

Risks = level of concern: High · Moderate · Low · Theoretical

  • No published human clinical trial safety data exists for the unmodified HGH Fragment 176-191 (all human data is for AOD-9604 derivative)

    High
  • High-dose administration caused hyperglycemia and reduced insulin sensitivity in rats (Ng & Bornstein 1978)

    Moderate
  • FDA has cited immunogenicity (immune reaction) concerns for the closely related AOD-9604 peptide

    Moderate
  • FDA has cited concerns about peptide impurity profiles in compounded formulations of related peptides

    Moderate
  • Limited long-term safety data — longest AOD-9604 trial was 24 weeks; no data for unmodified fragment

    Moderate
  • Quality control variability in unregulated products sold online

    High
  • Potential for degradation and loss of efficacy if improperly stored (peptide stability concerns)

    Low
  • Injection site reactions including redness, swelling, and irritation (reported anecdotally)

    Low
  • Transient headache reported anecdotally in user communities

    Low
  • Prohibited by WADA — positive test could result in sanctions for competitive athletes

    High
  • No data on safety during pregnancy or lactation

    Moderate
  • Extrapolating AOD-9604 safety data to the unmodified fragment involves scientific uncertainty — the single amino acid difference could alter immunogenicity, stability, or pharmacokinetics

    Moderate
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.